Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief.

A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD and asthma patients. This should result in significant healthcare cost savings as hospitalization is a key direct cost during an episode. There are currently no HRV vaccines in active clinical development.

The MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Rhinovirus vaccines across Western markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Rhinovirus spp, respiratory viruses, and related indications e.g. asthma and COPD. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel viral vaccines has also been utilised.

PRODUCT CONTENTS:
Published January 2016 (CAT No: VAMV066)

****This product is composed of one forecast model and a summary presentation.

Title page
Contents
Author’s note
Executive summary
HRV vaccines commercial model: key outputs
HRV vaccines: potential value ($m) by low/base/high price to 2030
HRV vaccines: potential value ($m) by target population (base price) to 2030
HRV vaccines: potential value ($m) by region (base price) to 2030
HRV vaccines: commercial model assumptions
The role of an HRV vaccine
HRV vaccine: points to note
Target markets for HRV vaccines
Major model inputs
HRV vaccine target product profile (TPP)
Drivers and resistors for a successful HRV vaccine
Disease burden caused by common respiratory viruses
Commercial parameters of respiratory viruses vaccines
HRV: background and epidemiology
Epidemiology: overview
Epidemiology: disease burden notes
Epidemiology: data – England 2009-2012
HRV disease burden: adults hospitalization (US)
HRV disease burden: respiratory viral infections and hospitalization
HRV disease burden: infants
HRV disease burden: elderly
HRV disease burden: elderly – comparative to other viruses
HRV disease burden: elderly – COPD
HRV disease burden: elderly – risk groups
HRV disease burden: asthma exacerbations
HRV disease burden: asthma exacerbations – association
HRV disease burden: asthma exacerbations – therapies

1 Model contents available upon application
2 Presentation titles may apply to more than one slide
Continued......

HRV disease burden: asthma exacerbations & HRV vaccine
HRV disease burden: asthma exacerbations – unmet need
HRV disease burden: COPD exacerbations
HRV disease burden: COPD exacerbations & viral infection
HRV disease burden: COPD exacerbations & disease severity
HRV disease burden: COPD exacerbations & related costs
HRV disease burden: COPD exacerbations & treatments
HRV disease burden: COPD exacerbations & economics
HRV disease burden: COPD exacerbations & HRV vaccine
HRV vaccines: R&D pipeline
Back-up: methodology
Methodology: populations (COPD)
Methodology: populations – COPD per country
Methodology: populations – asthma
Methodology: populations – asthma prevalence
Methodology: vaccine uptake
About VacZine Analytics
Disclaimer
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **$9995.00**/ GBP **£7000.00*** (Region license)*

* Indicative rate only. Prevailing rate applied to date of transaction.
* A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
5. CDC. Seasonal Influenza-Associated Hospitalizations in the United States. Available at: http://www.cdc.gov/flu/about/qa/hospital.htm
12. Tanner HE. Viral respiratory infections during the 2009 influenza A(H1N1) outbreak in the West Midlands Region, UK. Epidemiol Infect. 2012 Sep;140(9):1551-6.
22. CDC. Asthma FastStats. Available at: http://www.cdc.gov/nchs/fastats/asthma.htm


41. Welte T, Miravitlles M. Viral, bacterial or both? Regardless, we need to treat infection in COPD. Eur Respir J. 2014 Jul;44(1):11-3.


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.

5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on line invoices are payable within thirty days of the invoice date.

7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009